Grifols (GRFS) Competitors $8.95 -0.07 (-0.78%) Closing price 04:00 PM EasternExtended Trading$8.94 -0.01 (-0.17%) As of 04:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock GRFS vs. TEVA, ITCI, GMAB, SMMT, RDY, ASND, MRNA, VTRS, QGEN, and BPMCShould you be buying Grifols stock or one of its competitors? The main competitors of Grifols include Teva Pharmaceutical Industries (TEVA), Intra-Cellular Therapies (ITCI), Genmab A/S (GMAB), Summit Therapeutics (SMMT), Dr. Reddy's Laboratories (RDY), Ascendis Pharma A/S (ASND), Moderna (MRNA), Viatris (VTRS), Qiagen (QGEN), and Blueprint Medicines (BPMC). These companies are all part of the "pharmaceutical products" industry. Grifols vs. Its Competitors Teva Pharmaceutical Industries Intra-Cellular Therapies Genmab A/S Summit Therapeutics Dr. Reddy's Laboratories Ascendis Pharma A/S Moderna Viatris Qiagen Blueprint Medicines Teva Pharmaceutical Industries (NYSE:TEVA) and Grifols (NASDAQ:GRFS) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, community ranking, dividends, risk, media sentiment, institutional ownership, earnings, profitability and analyst recommendations. Does the media refer more to TEVA or GRFS? In the previous week, Teva Pharmaceutical Industries had 12 more articles in the media than Grifols. MarketBeat recorded 16 mentions for Teva Pharmaceutical Industries and 4 mentions for Grifols. Grifols' average media sentiment score of 1.04 beat Teva Pharmaceutical Industries' score of 0.19 indicating that Grifols is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Teva Pharmaceutical Industries 6 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral Grifols 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders & institutionals have more ownership in TEVA or GRFS? 54.0% of Teva Pharmaceutical Industries shares are held by institutional investors. 0.5% of Teva Pharmaceutical Industries shares are held by company insiders. Comparatively, 0.2% of Grifols shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Do analysts recommend TEVA or GRFS? Teva Pharmaceutical Industries presently has a consensus target price of $24.44, suggesting a potential upside of 40.44%. Given Teva Pharmaceutical Industries' higher probable upside, equities analysts plainly believe Teva Pharmaceutical Industries is more favorable than Grifols.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Teva Pharmaceutical Industries 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 2 Strong Buy rating(s) 3.20Grifols 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50 Which has more risk & volatility, TEVA or GRFS? Teva Pharmaceutical Industries has a beta of 0.6, indicating that its share price is 40% less volatile than the S&P 500. Comparatively, Grifols has a beta of 0.53, indicating that its share price is 47% less volatile than the S&P 500. Which has preferable valuation & earnings, TEVA or GRFS? Grifols has lower revenue, but higher earnings than Teva Pharmaceutical Industries. Teva Pharmaceutical Industries is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTeva Pharmaceutical Industries$16.62B1.20-$1.64B-$1.15-15.13Grifols$7.21B0.85$64.20M$1.177.65 Is TEVA or GRFS more profitable? Grifols has a net margin of 0.00% compared to Teva Pharmaceutical Industries' net margin of -9.91%. Teva Pharmaceutical Industries' return on equity of 42.46% beat Grifols' return on equity.Company Net Margins Return on Equity Return on Assets Teva Pharmaceutical Industries-9.91% 42.46% 6.65% Grifols N/A N/A N/A Is TEVA or GRFS a better dividend stock? Teva Pharmaceutical Industries pays an annual dividend of $1.0110 per share and has a dividend yield of 5.8%. Grifols pays an annual dividend of $0.36 per share and has a dividend yield of 4.0%. Teva Pharmaceutical Industries pays out -87.9% of its earnings in the form of a dividend. Grifols pays out 30.8% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Teva Pharmaceutical Industries is clearly the better dividend stock, given its higher yield and lower payout ratio. Does the MarketBeat Community prefer TEVA or GRFS? Teva Pharmaceutical Industries received 990 more outperform votes than Grifols when rated by MarketBeat users. Likewise, 67.95% of users gave Teva Pharmaceutical Industries an outperform vote while only 56.23% of users gave Grifols an outperform vote. CompanyUnderperformOutperformTeva Pharmaceutical IndustriesOutperform Votes134267.95% Underperform Votes63332.05% GrifolsOutperform Votes35256.23% Underperform Votes27443.77% SummaryTeva Pharmaceutical Industries beats Grifols on 15 of the 21 factors compared between the two stocks. Get Grifols News Delivered to You Automatically Sign up to receive the latest news and ratings for GRFS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GRFS vs. The Competition Export to ExcelMetricGrifolsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.16B$6.88B$5.60B$8.63BDividend YieldN/A2.49%5.27%4.19%P/E Ratio7.668.9127.3220.13Price / Sales0.85259.84411.80160.09Price / Cash9.5465.8538.2534.64Price / Book0.716.637.154.74Net Income$64.20M$143.71M$3.23B$247.80M7 Day Performance5.86%4.74%3.47%2.70%1 Month Performance25.10%15.14%12.95%10.03%1 Year Performance28.34%5.93%32.16%15.42% Grifols Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GRFSGrifols3.643 of 5 stars$8.95-0.8%N/A+26.9%$6.15B$7.21B7.6526,300TEVATeva Pharmaceutical Industries4.0837 of 5 stars$17.26+2.8%$24.50+42.0%+4.5%$19.56B$16.62B-11.9036,800ITCIIntra-Cellular Therapies0.8498 of 5 stars$131.87flat$109.70-16.8%N/A$14.05B$680.50M-151.57560GMABGenmab A/S3.7494 of 5 stars$21.77+3.9%$39.17+79.9%-18.2%$13.96B$3.12B12.511,660Positive NewsGap UpSMMTSummit Therapeutics2.9218 of 5 stars$17.73-2.7%$37.40+110.9%+176.7%$13.17B$700K-63.32110Trending NewsAnalyst ForecastAnalyst RevisionGap DownHigh Trading VolumeRDYDr. Reddy's Laboratories1.4049 of 5 stars$14.73+0.0%$17.00+15.4%+9.5%$12.29B$325.54B23.4524,800ASNDAscendis Pharma A/S3.254 of 5 stars$175.69+7.9%$216.07+23.0%+31.1%$10.71B$368.70M-24.75640Positive NewsAnalyst ForecastAnalyst RevisionMRNAModerna4.4132 of 5 stars$27.05+1.8%$53.58+98.1%-81.4%$10.46B$3.14B-2.913,900Trending NewsVTRSViatris2.1623 of 5 stars$8.69-1.1%$10.50+20.8%-14.0%$10.20B$14.33B-11.7437,000QGENQiagen3.135 of 5 stars$44.89-0.5%$48.42+7.9%+6.0%$9.98B$2.00B125.006,030BPMCBlueprint Medicines0.8504 of 5 stars$127.79+26.1%$125.69-1.6%+23.0%$8.25B$562.12M-118.32640High Trading Volume Related Companies and Tools Related Companies TEVA Alternatives ITCI Alternatives GMAB Alternatives SMMT Alternatives RDY Alternatives ASND Alternatives MRNA Alternatives VTRS Alternatives QGEN Alternatives BPMC Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GRFS) was last updated on 6/11/2025 by MarketBeat.com Staff From Our PartnersYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredWhy July 22nd Could Mean Big Changes for Social SecurityIn a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...Altimetry | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Grifols, S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share Grifols With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
